Biovie (BIVI) Debt Ratio (2016 - 2024)

Biovie (BIVI) posted Debt Ratio of 0.12 for Q3 2024, down 40.65% sequentially from 0.2 in Q2 2024, and down 5.83% YoY from 0.12 in Q4 2023.

Biovie (BIVI) Debt Ratio (2016 - 2024) Analysis & Trends

Biovie has reported Debt Ratio for 9 years, with the latest figure at 0.12 in Q3 2024.

Quarterly Debt Ratio fell 5.83% year-over-year to 0.12 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 0.12 (down 5.83% YoY) and the FY2024 annual result came in at 0.2, up 33.2% from the prior year.
Debt Ratio fell to 0.12 in Q3 2024 per BIVI's latest filing, from 0.2 in the prior quarter.
Over five years, Debt Ratio peaked at 0.66 in Q3 2022 and troughed at 0.0 in Q3 2020.
A 5-year average of 0.22 and a median of 0.16 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2021 and 2022: Debt Ratio sank 97.48% in 2021, then soared 9037.42% in 2022.
Over 5 years, Debt Ratio stood at 0.0 in 2020, then surged by 7407.37% to 0.35 in 2021, then retreated by 19.39% to 0.28 in 2022, then tumbled by 55.52% to 0.12 in 2023, then retreated by 5.83% to 0.12 in 2024.
According to Business Quant data, Debt Ratio over the past three periods registered 0.12, 0.2, and 0.12 for Q3 2024, Q2 2024, and Q3 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Biovie	14.17 Mn	14.17 Mn	-	-

Download Data